EPS for FibroGen, Inc. (FGEN) Expected At $-0.28; Cushing Asset Management LP Has Upped American Midstream Partners (AMID) Position

February 17, 2018 - By Adrian Erickson

Analysts expect FibroGen, Inc. (NASDAQ:FGEN) to report $-0.28 EPS on March, 7.They anticipate $0.26 EPS change or 48.15% from last quarter’s $-0.54 EPS. After having $-0.50 EPS previously, FibroGen, Inc.’s analysts see -44.00% EPS growth. The stock increased 0.09% or $0.05 during the last trading session, reaching $56.5. About 287,366 shares traded. FibroGen, Inc. (NASDAQ:FGEN) has risen 52.86% since February 17, 2017 and is uptrending. It has outperformed by 36.16% the S&P500.

Cushing Asset Management Lp increased American Midstream Partners (AMID) stake by 8.56% reported in 2017Q3 SEC filing. Cushing Asset Management Lp acquired 190,806 shares as American Midstream Partners (AMID)’s stock declined 17.59%. The Cushing Asset Management Lp holds 2.42M shares with $33.02 million value, up from 2.23M last quarter. American Midstream Partners now has $649.21 million valuation. The stock decreased 2.02% or $0.25 during the last trading session, reaching $12.1. About 72,033 shares traded. American Midstream Partners, LP (NYSE:AMID) has risen 15.28% since February 17, 2017 and is uptrending. It has underperformed by 1.42% the S&P500.

Among 8 analysts covering FibroGen Inc (NASDAQ:FGEN), 5 have Buy rating, 0 Sell and 3 Hold. Therefore 63% are positive. FibroGen Inc had 16 analyst reports since July 29, 2015 according to SRatingsIntel. The rating was initiated by Citigroup on Friday, December 4 with “Buy”. The company was initiated on Wednesday, September 23 by Lake Street. The stock has “Buy” rating by Stifel Nicolaus on Sunday, September 10. The firm has “Buy” rating by Stifel Nicolaus given on Wednesday, October 18. Goldman Sachs downgraded FibroGen, Inc. (NASDAQ:FGEN) on Friday, July 21 to “Neutral” rating. On Thursday, January 21 the stock rating was initiated by Credit Suisse with “Neutral”. The firm earned “Buy” rating on Tuesday, August 8 by Leerink Swann. The stock of FibroGen, Inc. (NASDAQ:FGEN) has “Buy” rating given on Monday, August 14 by Jefferies. The stock of FibroGen, Inc. (NASDAQ:FGEN) has “Hold” rating given on Wednesday, October 4 by Mizuho. As per Wednesday, July 29, the company rating was initiated by Citigroup.

FibroGen, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes therapeutic agents to treat serious unmet medical needs in the United States. The company has market cap of $4.63 billion. It is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases that is in Phase III clinical development for the treatment of anemia in chronic kidney disease; Pamrevlumab, a human-monoclonal antibody that inhibits the activity of connective tissue growth factor, which is in Phase II clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and Duchenne muscular dystrophy; and FG-5200 for the treatment of corneal blindness resulting from partial thickness corneal damage. It currently has negative earnings. It has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB.

Cushing Asset Management Lp decreased Anadarko Pete Corp (NYSE:APC) stake by 84,273 shares to 6,750 valued at $330,000 in 2017Q3. It also reduced Mrc Global Inc (NYSE:MRC) stake by 59,968 shares and now owns 491,876 shares. Plains All Amern Pipeline L (NYSE:PAA) was reduced too.

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


>